Peptides Similar to Amycretin

Peptides Related to Amycretin#

Amycretin is unique as the first-in-class single-molecule GLP-1/amylin receptor agonist. Its closest comparator is CagriSema, which targets the same two pathways but as a two-peptide combination. Amycretin's 24.3% weight loss at 36 weeks in Phase 1b/2a is among the highest reported for any single-molecule therapy.

CagriSema (Novo Nordisk)#

CagriSema is the most direct comparator since both target the same two pathways:

Both are Novo Nordisk programs. Amycretin represents the next generation, potentially replacing CagriSema if it demonstrates superior efficacy in Phase 3.

Semaglutide (Wegovy)#

Semaglutide is the GLP-1 monoagonist benchmark:

• Amycretin adds amylin receptor activity on top of GLP-1 agonism
• 24.3% weight loss versus ~15-17% for semaglutide at similar timepoints
• Both have oral formulations (both use SNAC)
• Semaglutide has extensive real-world and CV outcomes data

Tirzepatide (Zepbound)#

Tirzepatide and amycretin represent two different dual-mechanism approaches:

• Tirzepatide: GLP-1 + GIP receptors (approved)
• Amycretin: GLP-1 + amylin receptors (Phase 2)
• The amylin and GIP pathways affect appetite and metabolism through different mechanisms
• Phase 2/3 cross-trial comparison: amycretin 24.3% (36wk) vs tirzepatide 20.9% (72wk)

Retatrutide (Eli Lilly)#

Both are among the highest-efficacy obesity therapies in development:

• Retatrutide: ~24.2% weight loss in Phase 2 (triple agonist)
• Amycretin: 24.3% weight loss in Phase 1b/2a (dual agonist)
• Different receptor targets but comparable efficacy

Summary Comparison#

Comparison Context#

Amycretin belongs to the Metabolic category of research peptides. Comparing Amycretin with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.

Detailed Comparisons#

The following peptides and compounds are most closely related to Amycretin in mechanism, indication, or therapeutic category:

Amycretin vs CagriSema#

Similarity: Very High - Both target GLP-1 and amylin receptors for obesity. CagriSema uses two separate peptides; amycretin combines both in one molecule.

Key Differences: CagriSema is a two-peptide combination (cagrilintide + semaglutide); amycretin is a single molecule. CagriSema has Phase 3 data (20.4% weight loss in REDEFINE 1) and NDA filed. Amycretin showed 24.3% at 36 weeks in Phase 1b/2a.

Advantages of CagriSema: Single molecule (simpler), higher weight loss (24.3% vs 20.4%), both SC and oral formulations, novel first-in-class approach

Disadvantages of CagriSema: Much earlier development stage (Phase 2 vs NDA filed), smaller evidence base, higher GI event rates reported (82% nausea), no active comparator

Researchers choosing between Amycretin and CagriSema should consider the development stage, available evidence, and specific research objectives when making their selection.

Amycretin vs Semaglutide#

Similarity: High - Both are GLP-1 receptor agonists; amycretin adds amylin receptor activation in the same molecule

Key Differences: Semaglutide is a selective GLP-1 agonist; amycretin adds amylin activity. Semaglutide is approved with extensive safety and CV outcomes data. Both have oral formulations.

Advantages of Semaglutide: Dual GLP-1/amylin mechanism provides additive weight loss, 24.3% vs ~15-17% for semaglutide

Disadvantages of Semaglutide: Not approved (semaglutide has years of real-world data), higher GI event rates, smaller evidence base, no CV outcomes

Researchers choosing between Amycretin and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.

Amycretin vs Tirzepatide#

Similarity: High - Both are dual-receptor agonists for obesity, but target different second receptors (amylin vs GIP)

Key Differences: Tirzepatide targets GLP-1 + GIP; amycretin targets GLP-1 + amylin. Fundamentally different second receptor and different metabolic effects. Tirzepatide is FDA-approved.

Advantages of Tirzepatide: Higher Phase 2 weight loss (24.3% vs 20.9%), oral formulation in development, potentially different metabolic profile via amylin

Disadvantages of Tirzepatide: Much earlier development (Phase 2 vs approved), no head-to-head data, no CV outcomes, higher GI rates

Researchers choosing between Amycretin and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.

Amycretin vs Retatrutide#

Similarity: Moderate - Both are next-generation multi-receptor obesity therapies with different receptor targets

Key Differences: Retatrutide is a triple agonist (GIP + GLP-1 + glucagon); amycretin is a dual agonist (GLP-1 + amylin). Different additional pathways (glucagon vs amylin).

Advantages of Retatrutide: Dual formulation (SC + oral), amylin pathway for appetite regulation

Disadvantages of Retatrutide: Comparable peak weight loss (~24.3% vs ~24.2%), no glucagon receptor activity for hepatic benefits, both in Phase 2-3

Researchers choosing between Amycretin and Retatrutide should consider the development stage, available evidence, and specific research objectives when making their selection.

Amycretin vs CT-388#

Similarity: Moderate - Both are dual-receptor agonists in development, targeting different receptor combinations

Key Differences: CT-388 targets GLP-1 + GIP with signal-biased mechanism; amycretin targets GLP-1 + amylin. Different second receptors and different molecular approaches.

Advantages of CT-388: Higher peak weight loss (24.3% vs 22.5%), oral formulation, targets amylin pathway

Disadvantages of CT-388: Similar development stage, higher GI event rates, less novel signaling mechanism compared to CT-388 biased agonism

Researchers choosing between Amycretin and CT-388 should consider the development stage, available evidence, and specific research objectives when making their selection.

Related Reading#

• Amycretin overview and research guide
• Amycretin research evidence
• Amycretin dosing protocols